Drug Database
IN

interferon (Alfaferone)

✓ Approved

Johnson & Johnson Services, Inc. · IFNAR2

什么是 interferon?

interferon 是一种治疗药物,由Johnson & Johnson Services, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Others、Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Alfaferone
公司Johnson & Johnson Services, Inc.
分子靶点IFNAR2
给药途径Others, Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

interferon 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

interferon 针对 9 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hairy cell leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Nervous system disordersMultiple sclerosis✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedNature communications2026-11-19

Tumor-intrinsic PTPN12 suppresses anti-tumor immunity in colorectal cancer by restraining a dual epigenetic and cytoskeletal dsRNA sensing program.

Huo Yachang Y, Tian Yijun Y, Wang Dan D, Ping Yu Y et al.

Innate sensing of endogenous double-stranded RNA and the ensuing interferon response are crucial for the efficacy of immune checkpoint inhibition. Microsatellite stable colorectal cancer characteristically lacks this response, remaining immune-refractory with undefined intrinsic regulators. Here, through an in vivo clustered regularly interspaced short palindromic repeats screen, we identify PTPN12 as a physiological barrier that suppresses double-stranded RNA sensing and interferon response. TRIM28 was identified as a direct PTPN12 substrate here; PTPN12 removes phosphorylation at Y370 to stabilize repressive complexes and silence transposable elements, while concurrently rewiring the adhesive cytoskeleton to disrupt the spatially organization of cytosolic double-stranded RNA required for efficient innate sensing. Pharmacological inducible PTPN12 knockdown inhibits pre-established tumor growth and overcomes immunotherapy resistance in vivo, recapitulating PTPN12 ablation-induced massive double-stranded RNA accumulation. Our findings reveal a role for PTPN12 in coupling epigenetic silencing with cytoskeletal surveillance, suggesting potential strategies to augment anti-tumor immunity and overcome immunotherapy resistance in microsatellite stable colorectal cancer.

PMID 43052240
阅读全文 →
PubMedPulmonology2026-11-19

Nebulized interferon-β1a (SNG001) in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.

Qin Jinlv J, Wang Guizuo G, Han Dong D

This systematic review and meta-analysis aimed to determine the efficacy of nebulised interferon-β1a (SNG001) in patients with Coronavirus disease-2019 (COVID-19). A systematic search was conducted across PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Studies were searched up to November 2025. Randomised controlled trials (RCTs) on treatment of COVID-19 with SNG001, compared with placebo or standard of care, were reviewed. Data were analysed using the RevMan Version 5.1 (The Cochrane Collaboration). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Four RCTs (enrolling 1055 participants) met the inclusion criteria. The proportion of patients with hospitalisations (data extracted from two RCTs) (RR 0.16, 95% CI 0.03 to 0.88), and serious adverse events (RR 0.65, 95% CI 0.47 to 0.90) were significantly fewer in SNG001 groups. There was no statistically significant difference in all-cause mortality (RR 0.72, 95% CI 0.37 to 1.39), patients non-recovery at day 28 (RR 0.87, 95% CI 0.65 to 1.17), and adverse event (RR 0.97, 95% CI 0.90 to 1.04) between the two groups. Nebulised SNG001 was safe and associated with a reduction in COVID-19-related hospital admission. SNG001 shows a potential benefit for outpatients with COVID-19, but it requires larger clinical trials for future validations, particularly in vaccinated and previously infected populations.

PMID 43053745
阅读全文 →
PubMedAlzheimer's research & therapy2026-11-19

Resting-state EEG features of cognitive fluctuations across the Lewy body disease spectrum.

Negida Ahmed A, Lageman Sarah K SK, Ono Kenchiro K, Ahsan Md Moinul MM et al.

Cognitive fluctuations (CF) are a core feature of Lewy body dementia (LBD) that negatively impact quality of life. Despite their prevalence and negative impact, CF are challenging to identify clinically. The goal of this study was to identify easily obtainable EEG features associated with CF across the spectrum of Lewy body disease (LB). We conducted a cross-sectional study of 53 patients prospectively enrolled through the outpatient clinics of the Department of Neurology at Virginia Commonwealth University. Based on the Clinician Assessment of Fluctuations, participants were categorized as LB disease without CF (LB-CF) or LB disease with CF (LB + CF). All participants underwent a resting-state EEG recording with eyes closed for at least 3 min. EEG data were preprocessed and the following features were extracted: dominant frequency (DF), dominant frequency variability (DFV), dominant frequency prevalence (DFP), and individual alpha peak frequency (IAF). We applied Kruskal-Wallis tests and logistic regression models to evaluate differences in EEG features between study groups. We analyzed EEG features for 29 LB + CF and 24 LB-CF participants. Compared to the LB-CF group, the LB + CF group had significantly lower DF, DFP-alpha, and IAF in all derivations (all p < 0.05). In logistic regression analysis adjusting for age, sex, and MoCA score, these EEG features remained significant predictors of group (LB + CF vs. LB-CF, all q < 0.05). The elastic-net logistic regression model identified five predictors (anterior DFP-alpha, anterior DFP-pre-alpha, anterior DF, temporal DF, and temporal IAF) achieving an AUC of 0.86, whereas anterior DFP-alpha alone achieved an AUC of 0.85. Among patients with LB disease, resting-state EEG features were associated with CF and were significant predictors of CF even after adjustment for age, sex, and MoCA. The development of an EEG-based biomarker of CF using this set of features could improve diagnosis of Lewy body dementia.

PMID 43053228
阅读全文 →
PubMedInternational journal of urology : official journal of the Japanese Urological Association2026-11-19

Re: A Novel Alpha-Numeric Classification of Urethral Duplication and Triplication-Proposal for a "Blind-Ending" Suffix.

Cayirli Hasan H, Beci Faruk F

PMID 43053266
阅读全文 →
PubMedBrain and behavior2026-11-19

Tracking Neurophysiological Trajectories in Adolescent Non-Suicidal Self-Injury During Mindfulness-Based Intervention: A Longitudinal Single-Channel EEG Study.

Tong B G BG, He Xuemei X, Ren Rui R, Yu Yuanyuan Y et al.

Adolescent non-suicidal self-injury (NSSI) remains a major clinical challenge, and objective neurophysiological monitoring during early intervention is lacking. This prospective longitudinal observational study characterized longitudinal EEG trajectories during an individualized home-based EEG biofeedback editation (H-EBM) intervention in hospitalized adolescents with NSSI and explored whether neurophysiological trajectory features were associated with emotional improvement. Fifty-two hospitalized adolescents with NSSI (DSM-5 criteria) who received routine inpatient psychiatric care together with daily H-EBM sessions over approximately 10 days were included in the per-protocol analysis. H-EBM integrated metaphor-guided therapeutic narratives with real-time EEG biofeedback via a single-lead device (Fp1, 512 Hz). Emotional states were assessed at admission and discharge using the profile of mood states (POMS). Participants were exploratorily classified into exploratory responder ( n = 36 ) and non-responder ( n = 16 ) subgroups based on total mood disturbance (TMD) improvement. Longitudinal alpha/beta power ratio trajectories were compared between subgroups, and associations between EEG trajectory slopes and TMD improvement were examined. The exploratory responder subgroup showed significant reductions in TMD scores and core symptom subscales (depression and tension; all p < 0.001 ), whereas the exploratory non-responder subgroup showed no improvement. The alpha/beta ratio in the exploratory responder subgroup exhibited a progressive upward trajectory across training sessions, while this ratio remained stable or fluctuated in the exploratory non-responder subgroup. The alpha/beta ratio slope was positively associated with TMD improvement scores (Pearson r = 0.43 , 95% CI [0.18, 0.63], p = 0.002 ). Exploratory logistic regression suggested that the alpha/beta ratio slope was associated with exploratory responder status after adjusting for age and gender (OR = 9.49, 95% CI [1.01, 89.44], p = 0.049 ). Exploratory ROC analysis showed moderate apparent (in-sample) discriminative performance (AUC = 0.774, 95% CI [0.638, 0.899]). Longitudinal neurophysiological trajectories during individualized H-EBM were associated with emotional improvement in hospitalized adolescents with NSSI. These preliminary findings suggest that EEG trajectory analysis may represent a promising objective monitoring approach during individualized mindfulness-based interventions. Given the observational design without a control group, future randomized controlled studies are warranted to examine potential therapeutic effects.

PMID 43053476
阅读全文 →
PubMedBMC neurology2026-11-19

Turkish validity and reliability of the Migraine Treatment Optimization Questionnaire-4 (MTOQ-4).

Aksoy Hilal H, Yıldız Nadide N, Fidanci Izzet I, Ayhan Başer Duygu D

The Migraine Treatment Optimization Questionnaire-4 (MTOQ-4) is a brief patient-reported instrument developed to evaluate the effectiveness of acute migraine treatment. This study aimed to assess the validity and reliability of the Turkish version of MTOQ-4. This methodological study was conducted between May and November 2025. After obtaining permission from the scale developer, the translation and cultural adaptation process included forward translation, expert panel review, back translation, and pilot testing. The study population consisted of adults diagnosed with migraine who attended a family medicine outpatient clinic. Sociodemographic data and the MTOQ-4 were administered face-to-face. Internal consistency was assessed using Cronbach's alpha. Construct validity was evaluated using exploratory factor analysis. Kaiser-Mayer-Olkin(KMO) and Bartlett's tests were applied to assess sample adequacy. Statistical analyses were performed using SPSS 23 and AMOS. The mean content validity index (S-CVI/Ave) at the scale level was calculated as 0.95. The Cronbach's Alpha coefficient, calculated to determine the internal consistency of the MTOQ-4 scale, was found to be 0.829. The KMO value was determined as 0.7887, and the Bartlett test was statistically significant (p < 0.001). The exploratory factor analysis showed that all factor loadings were above 0.60. The Turkish version of MTOQ-4 is expected to be a valid and reliable instrument for evaluating acute migraine treatment effectiveness in primary care.

PMID 43052836
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多interferon